- Home
- INSW vs XENE Comparison
INSW vs XENE Comparison
Compare INSW & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INSW | XENE |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | INSW | XENE |
|---|---|---|
| Price | $124.87 | $34.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 19 |
| Target Price | ★ $119.83 | $72.43 |
| AVG Volume (30 Days) | 740.3K | ★ 2.6M |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | ★ 10.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 11.66 | N/A |
| Revenue | ★ $843,302,000.00 | $311,000.00 |
| Revenue This Year | $70.53 | N/A |
| Revenue Next Year | N/A | $2,045.70 |
| P/E Ratio | $10.65 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $43.29 | $35.06 |
| 52 Week High | $125.40 | $72.66 |
Technical Indicators
Market Signals| Indicator | INSW | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 75.45 | 20.58 |
| Support Level | $75.16 | N/A |
| Resistance Level | N/A | $43.68 |
| Average True Range (ATR) | 3.93 | 1.27 |
| MACD | 1.03 | 0.40 |
| Stochastic Oscillator | 96.77 | 0.63 |
Price Performance
Historical ComparisonAbout INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. Its fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.